C3 and infection: We further analyzed the number and proportion of infection-related adverse event reports under different complement inhibitor categories (C3 inhibitors, C5 inhibitors, and Factor B inhibitors) (Figure 2B) and found that a higher number of reports were associated with C5 inhibitor treatment, which might be related to the broad indications and higher clinical usage volume of this type of inhibitor.